

Tabla Suplementaria 1. Estudios excluidos y motivo de exclusión.

Estudio	Razón de exclusión
Alberici, F(1) Aldea, JJ(2)	Datos de neuropatía faltantes o no especificados
Blaes, F(3)	Revisión narrativa, no revisión sistemática
Braun-Moscovici, Y(4)	Revisión narrativa, no revisión sistemática
Butterly, Sj(5)	Datos de neuropatía faltantes o no especificados
Charles, P(6)	Datos de neuropatía faltantes o no especificados
Choudhry, M(7)	Caso clínico
Da Silca, LS(8)	Datos de neuropatía faltantes o no especificados
Eriksson, P(9)	Datos de neuropatía faltantes o no especificados
Gorson, KC(10)	Tipo de neuropatía no especificado
Gottenberg,JE(11)	Tipo de neuropatía no especificado
Kelly,JJ (12)	Caso clínico
Moog,P (13)	Caso clínico
Piccione, E(14)	Eficacia de RTX no evaluado
Zenone,T(15)	Datos de neuropatía faltantes o no especificados
Zhang,W (16)	Eficacia de RTX no evaluado
Perna (17)	Revisión narrativa, no revisión sistemática
Ghinoi, A(18)	Revisión narrativa, no revisión sistemática
Puechal, X(19)	Revisión narrativa, no revisión sistemática
Noronha, V (20)	Revisión narrativa, no revisión sistemática
Nobile-orazio, E(21)	Revisión narrativa, no revisión sistemática
Gwathmey, KG(22)	Revisión narrativa, no revisión sistemática
Holle, JU (23)	Revisión narrativa, no revisión sistemática
Bril, V (24)	Revisión narrativa, no revisión sistemática
Bosch, X (25)	Datos de neuropatía faltantes o no especificados

RTX: Rituximab

1. Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. *Rheumatology (United Kingdom)*. 2015;54(7):1153-60.
2. Aldea JJ. [Monoclonal antibodies in inflammatory disease of the muscle and peripheral nervous system]. *Neurologia*. 2012;27(1):39-45.
3. Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. *Ther Adv Musculoskelet Dis*. 2015;7(2):45-55.
4. Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, Toledano K, Markovits D, Rozin A, et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. *Rheumatol Int*. 2013;33(6):1495-504.

5. Butterly SJ, Pillans P, Horn B, Miles R, Sturtevant J. Off-label use of rituximab in a tertiary Queensland hospital: ORIGINAL ARTICLE. *Internal Medicine Journal*. 2010;40(6):443-52.
6. Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients. *Rheumatology (United Kingdom)*. 2014;53(3):532-9.
7. Choudhry M, Rao N, Juneja R. Successful treatment of cryoglobulinaemia with rituximab. *Case Rep Nephrol Urol*. 2012;2(1):72-7.
8. da Silva LS, de Campos KVM, de Melo AKG, de Brito DCSE, Braz AS, Medeiros Freire EA. Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: Report of seven cases and literature review. *Revista Brasileira de Reumatologia*. 2015;55(6):531-5.
9. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. *J Intern Med*. 2005;257(6):540-8.
10. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. *Muscle Nerve*. 2007;35(1):66-9.
11. Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. *Annals of the Rheumatic Diseases*. 2013;72(6):1026-31.
12. Kelly JJ. Chronic peripheral neuropathy responsive to rituximab. *Rev Neurol Dis*. 2006;3(2):78-81.
13. Moog P, Thuermel K. Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. *Ther Clin Risk Manag*. 2015;11:1749-58.
14. Piccione E, Salame K, Katirji B. Vasculitic neuropathy associated with concomitant active hepatitis C and B. *Neurology*. 2013;80(1).
15. Zenone T. Flare of essential mixed cryoglobulinemic vasculitis with hemorrhagic bullous purpura after rituximab infusion. *International Journal of Rheumatic Diseases*. 2013;16(2):237-9.
16. Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. *Clinical and Experimental Rheumatology*. 2009;27(1 SUPPL. 52):S65-S9.
17. Perna P, Cioffi R, Merchionda A, Moscato P, Raimo S, Caputo D. Myxed cryoglobulinemia treated with rituximab. *Italian Journal of Medicine*. 2013;7:94.
18. Ghinoi A, Mascia MT, Puccini R, Ferri C. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)]. *G Ital Nefrol*. 2004;21(3):225-37.
19. Puéchal X, Guillevin L. Therapeutic immunomodulation in systemic vasculitis: Taking stock. *Joint Bone Spine*. 2013;80(4):374-9.
20. Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. *J Clin Oncol*. 24. United States 2006. p. e3.
21. Nobile-Orazio E. Treatment of dys-immune neuropathies. *J Neurol*. 2005;252(4):385-95.
22. Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. *Lancet Neurol*. 2014;13(1):67-82.
23. Holle JU, Laudien M, Gross WL. Clinical Manifestations and Treatment of Wegener's Granulomatosis. *Rheumatic Disease Clinics of North America*. 2010;36(3):507-26.
24. Bril V, Katzberg HD. Acquired immune axonal neuropathies. *Continuum (Minneapolis)*. 2014;20(5 Peripheral Nervous System Disorders):1261-73.
25. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: A systematic review. *Journal of the American Medical Association*. 2007;298(6):655-69.

